文献速递类风湿关节炎

Mavrilimumab(全人源粒细胞-巨噬细胞集落刺激因子受体α单克隆抗体)在类风湿关节炎患者中的长期安全性和有效性

Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2018-03-31

本文报告了Mavrilimumab在两项IIb期研究(1071和1107)及一项开放标签延伸研究中的长期安全性和有效性。共442例患者接受Mavrilimumab治疗,累积安全性暴露899患者年,中位治疗时间2.5年。最常见治疗中出现的不良事件为鼻咽炎和支气管炎,肺功能变化多为短暂性;100 mg每2周方案显示出持续疗效,第122周65.0%患者达到DAS28-CRP<3.2,40.6%达到DAS28-CRP<2.6,长期治疗耐受性良好且未增加治疗中出现的不良事件发生率。

要点

  • Mavrilimumab 100 mg每2周联合甲氨蝶呤在类风湿关节炎中显示出持续疗效,第122周65.0%患者达到DAS28-CRP<3.2。
  • 累积安全性暴露899患者年,中位治疗2.5年,最常见治疗中出现的不良事件为鼻咽炎(7.68/100患者年)和支气管炎(5.68/100患者年)。
  • 第74周和第104周分别有3.5%和6.2%患者出现第1秒用力呼气容积下降,肺功能变化多为短暂性。

核心结论

  • 长期Mavrilimumab治疗维持了疗效且耐受性良好,未增加治疗中出现的不良事件发生率。
  • 安全性数据与两项IIb期 qualifying 研究相当。

研究设计与样本

  • 研究包括两项IIb期研究(1071和1107)及一项开放标签延伸研究(ClinicalTrials.gov标识符:NCT01712399)。
  • 研究1071中,对改善病情抗风湿药(DMARDs)应答不足的患者接受Mavrilimumab(30、100或150 mg)或安慰剂每2周一次联合甲氨蝶呤。
  • 研究1107中,对抗肿瘤坏死因子药物和/或DMARDs应答不足的患者接受Mavrilimumab 100 mg每2周一次或戈利木单抗50 mg每4周一次联合甲氨蝶呤。
  • 进入开放标签延伸研究的患者接受Mavrilimumab 100 mg每2周一次联合甲氨蝶呤。
  • 共442例患者接受Mavrilimumab治疗,累积安全性暴露899患者年,中位治疗时间2.5年(范围0.1-3.3年)。

主要发现

  • 最常见治疗中出现的不良事件为鼻咽炎(n=69;7.68/100患者年)和支气管炎(n=51;5.68/100患者年)。
  • 第74周和第104周分别有3.5%和6.2%患者出现第1秒用力呼气容积下降(较基线下降>20%至<80%预计值)。
  • 第74周和第104周分别有2.9%和3.4%患者出现用力肺活量下降(较基线下降>20%至<80%预计值)。
  • 多数肺部变化为短暂性,仅偶尔与不良事件相关。
  • Mavrilimumab 100 mg每2周一次显示出持续疗效;第122周65.0%患者达到DAS28-CRP<3.2,40.6%患者达到DAS28-CRP<2.6。

关键数值与推荐

  • 第122周65.0%患者达到DAS28-CRP<3.2。
  • 第122周40.6%患者达到DAS28-CRP<2.6。
  • 鼻咽炎发生率7.68/100患者年(n=69)。
  • 支气管炎发生率5.68/100患者年(n=51)。
  • 第74周和第104周分别有3.5%和6.2%患者出现第1秒用力呼气容积下降。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Mavrilimumab, a human monoclonal antibody, targets granulocyte-macrophage colony-stimulating factor receptor α. We undertook to determine the long-term safety and efficacy of mavrilimumab in rheumatoid arthritis patients in 2 phase IIb studies (1071 and 1107) and in 1 open-label extension study (ClinicalTrials.gov identifier: NCT01712399). METHODS: In study 1071, patients with an inadequate response to disease-modifying antirheumatic drugs (DMARDs) received mavrilimumab (30, 100, or 150 mg) or placebo every other week plus methotrexate. In study 1107, patients with an inadequate response to anti-tumor necrosis factor agents and/or DMARDs received 100 mg mavrilimumab every other week or 50 mg golimumab every 4 weeks plus methotrexate. Patients entering the open-label extension study received 100 mg mavrilimumab every other week plus methotrexate. Long-term safety and efficacy of mavrilimumab were assessed. RESULTS: A total of 442 patients received mavrilimumab (14 of 245 patients from study 1071, 9 of 70 patients from study 1107, and 52 of 397 patients from the open-label extension study discontinued mavrilimumab treatment throughout the studies). The cumulative safety exposure was 899 patient-years; the median duration of mavrilimumab treatment was 2.5 years (range 0.1-3.3 years). The most common treatment-emergent adverse events (AEs) were nasopharyngitis (n = 69; 7.68 per 100 patient-years) and bronchitis (n = 51; 5.68 per 100 patient-years). At weeks 74 and 104, 3.5% and 6.2% of patients, respectively, demonstrated reduction in forced expiratory volume in 1 second, while 2.9% and 3.4% of patients, respectively, demonstrated reduction in forced vital capacity (>20% reduction from baseline to <80% predicted). Most pulmonary changes were transient and only infrequently associated with AEs. Mavrilimumab at 100 mg every other week demonstrated sustained efficacy; at week 122, 65.0% of patients achieved a Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) of <3.2, and 40.6% of patients achieved a DAS28-CRP of <2.6. CONCLUSION: Long-term treatment with mavrilimumab maintained response and was well-tolerated with no increased incidence of treatment-emergent AEs. Safety data were comparable with those from both phase IIb qualifying studies.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Burmester GR, McInnes IB, Kremer JM, et al. Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2018. PMID: 29361199. doi:10.1002/art.40420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。